Key clinical point: The Disease Activity index for Psoriatic Arthritis (DAPSA) based on a quick quantitative C-reactive protein (qCRP) assay (Q-DAPSA) showed perfect agreement with conventional DAPSA in the majority of patients with PsA.
Major finding : Overall, 98.1% of patients were similarly categorized into disease activity groups (remission and low, moderate, and high disease activity) using Q-DAPSA and DAPSA, with both indices showing identical numerical values in 57.7% of patients.
Study details : Findings are from a multicenter, cross-sectional study including 104 patients with PsA and available CRP values (measured by routine laboratory and quick qCRP assays) .
Disclosures: This study was partially supported by Novartis. The authors declared receiving grants, personal fees, or support for attending meetings and travels from Novartis and other sources.
Source: Proft F et al. Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: A prospective multicentre cross-sectional study. RMD Open. 2022;8:e002626 (Nov 2). Doi: 10.1136/rmdopen-2022-002626